Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

SAGE Therapeutics Inc (SAGE) USD0.0001

Sell:$46.88 Buy:$46.94 Change: $1.50 (3.30%)
Market closed |  Prices as at close on 27 September 2021 | Switch to live prices |
Sell:$46.88
Buy:$46.94
Change: $1.50 (3.30%)
Market closed |  Prices as at close on 27 September 2021 | Switch to live prices |
Sell:$46.88
Buy:$46.94
Change: $1.50 (3.30%)
Market closed |  Prices as at close on 27 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

Contact details

Address:
215 1st St
CAMBRIDGE
02142-1213
United States
Telephone:
+1 (617) 2998380
Website:
https://www.sagerx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SAGE
ISIN:
US78667J1088
Market cap:
$2.67 billion
Shares in issue:
58.81 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Barry Greene
    President, Chief Executive Officer, Director
  • Kimi Iguchi
    Chief Financial Officer, Treasurer
  • Anne Cook
    Senior Vice President, General Counsel, Corporate Secretary
  • Albert Robichaud
    Chief Scientific Officer
  • Jeffrey Jonas
    Chief Innovation Officer, Director
  • Chris Benecchi
    Chief Commercial Officer
  • Stephen Kanes
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.